查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014688

基因檢測市場：2026-2032年全球市場預測（按產品類型、檢測類型、技術、應用、分銷管道和最終用戶分類）

Genetic Testing Market by Product, Test Type, Technology, Application, Distribution Channel, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，基因檢測市場價值將達到 154.4 億美元，到 2026 年將成長到 176 億美元，到 2032 年將達到 397.2 億美元，複合年成長率為 14.44%。

主要市場統計數據
基準年 2025 154.4億美元
預計年份：2026年 176億美元
預測年份 2032 397.2億美元
複合年成長率 (%) 14.44%

全面實施基因檢測生態系統，重點在於臨床整合、消費者參與、監管發展和營運擴充性。

基因檢測領域正經歷快速發展，這主要得益於分子技術的進步、臨床應用的拓展以及消費者對個人化醫療日益成長的需求。診斷實驗室、醫院和直接面對消費者的銷售管道正在將先進的檢測方法整合到其工作流程中，同時，軟體和服務也日益支持對檢測結果的解讀、報告和長期數據管理。這些趨勢的融合正在重塑醫療服務提供者、保險公司和患者獲取基因資訊的方式。

遺傳學領域的變革性變化是由整合測試平台、雲端原生解讀、不斷發展的交付模式和增強的法規結構所驅動的。

基因檢測領域正從孤立的檢測轉向整合的、數據驅動的服務，這些服務融合了檢查室能力、分析軟體和持續的臨床決策支援。定序和PCR平台正與基因表現和微陣列工具相輔相成，而基於雲端的生物資訊學正在加速檢測結果的交付並提高突變分析的準確性。這些技術的融合使得更全面的診斷方案成為可能，並促進了貫穿整個臨床路徑的多模態檢測策略。

評估 2025 年關稅措施如何重組基因檢測相關人員的採購、供應鏈和業務永續營運。

美國2025年實施的關稅政策，為整個基因檢測生態系統的採購、供應鏈策略和成本管理引入了新的變數。儀器和耗材製造商被迫重新評估其籌資策略，檢測實驗室也需要評估進口試劑和設備的總到岸成本。為此，相關人員正在重新分配採購數量，加強供應商多元化，並探索在地化生產方案，以減輕關稅相關價格波動的影響。

深入了解全面的細分，以便在技術、測試類型、應用、通路和最終用戶方面協調產品開發、商業化和營運重點。

深入了解市場區隔對於制定產品策略和確定投資優先順序至關重要。從產品類型角度來看，相關人員需要區分驅動持續收入和資本支出週期的耗材和設備，以及透過分析、報告和工作流程整合來建立長期客戶關係的軟體和服務。每個產品類型都有不同的市場准入要求和服務架構。

從區域觀點看美洲、歐洲、中東和非洲以及亞太市場在監管差異、實施速度和供應鏈本地化方面的細微差別。

區域趨勢持續對技術採納曲線、監管預期和夥伴關係策略產生顯著影響。在美洲，科技融入臨床實踐以及消費者意識的提升正在推動對多樣化檢測組合的需求，而相關人員則受益於完善的報銷機制和緊密的臨床網路，這些機制和網路為創新診斷技術的試驗提供了支持。隨著醫療模式向整合式醫療模式轉變，醫療機構正日益將基因組分析成果融入慢性病管理和腫瘤治療路徑中，這反過來又推動了對本地檢測能力和結果解讀服務的投資。

主要企業透過平台整合、夥伴關係、資料互通性和卓越營運展現策略差異化的趨勢。

基因檢測領域的競爭格局由成熟的儀器製造商、專業的檢測方法開發公司、生物資訊學提供者和綜合服務實驗室組成。主要參與者透過平台廣度、分析演算法和附加價值服務（例如變異註釋、真實世界數據 (RWE) 生成和臨床醫生培訓）來脫穎而出。隨著互通性和數據標準的重要性日益凸顯，投資強大的應用程式介面 (API) 和電子健康記錄(EHR) 整合的公司正在臨床環境中獲得競爭優勢。

針對平台柔軟性、供應鏈彈性、資料互通性、監管參與和建構持續臨床服務等方面的經營團隊實用建議。

產業領導企業應採取多管齊下的策略，以確保其在基因檢測領域的長期地位和影響力。首先，應優先投資模組化平台，以便快速引入新的檢測方法並提供靈活的服務層級。這將縮短新興臨床應用的上市時間，並支援面向不同類型客戶的擴充性。其次，供應商應多元化和區域採購制度化，以減輕關稅和物流中斷的影響，同時確保品質和檢驗進度。

採用穩健的混合調查方法，結合相關人員訪談、文獻整合、檢驗和專家同行評審，確保獲得實用且檢驗的見解。

本分析的調查方法結合了定性和定量方法，旨在得出可操作且可重複的見解。主要研究包括對實驗室主任、醫院採購經理、臨床遺傳學家和企業高管進行結構化訪談，以了解他們對技術選擇、報銷挑戰和營運重點的第一手觀點。次要研究涵蓋了同行評審文獻、技術白皮書、監管指導文件和公開的企業資訊披露，以將主要研究結果置於更廣闊的背景中，並確保其符合當代標準。

總結結論，整合了負責任的實施、營運嚴謹性、監管合作以及夥伴關係為主導的基因檢測成長所面臨的策略挑戰。

總而言之，基因檢測領域正處於一個轉折點，技術成熟、監管完善和醫療模式不斷演進三者交匯融合，創造了重要的策略機會。那些將產品開發與檢驗的臨床效用相結合、投資於可互通的數據基礎設施並增強供應鏈韌性的機構，將最有利於獲得長期價值。同時，與監管機構積極合作以及嚴謹的證據收集對於擴大臨床應用和確保永續的報銷途徑仍然至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 基因檢測市場：依產品分類

  • 耗材/設備
  • 軟體服務

第9章 基因檢測市場：檢測類型

  • 基因帶原檢測
  • 診斷測試
  • 新生兒篩檢
  • 藥物基因體學
  • 胚胎著床前檢測
  • 產前檢查
  • 無症狀/預測性檢測

第10章 基因檢測市場：依技術分類

  • 細胞遺傳學
  • DNA定序
  • 基因表現分析
  • 微陣列
  • PCR

第11章：基因檢測市場：依應用領域分類

  • 自體免疫疾病
  • 癌症
  • 慢性病
  • 遺傳性疾病
  • 神經退化性疾病

第12章 基因檢測市場：依分銷管道分類

  • 離線
  • 線上

第13章：基因檢測市場：依最終用戶分類

  • 診斷檢查室
  • 家庭環境
  • 醫院和診所

第14章 基因檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 基因檢測市場：依群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 基因檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國基因檢測市場

第18章：中國基因檢測市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Bruker Corporation
  • Centogene NV
  • Color Health, Inc.
  • CooperSurgical Inc.
  • Editas Medicine, Inc.
  • Eugene Labs Pty Ltd.
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche AG
  • Fulgent Genetics, Inc.
  • Gene by Gene, Ltd.
  • GeneDx, LLC
  • Illumina, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Living DNA Ltd.
  • Macrogen, Inc.
  • MyHeritage Ltd.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Newtopia Inc.
  • PathogenDx Corporation
  • PerkinElmer Inc.
  • Qiagen NV
  • Quest Diagnostics Incorporated
  • Sanofi SA
  • Thermo Fisher Scientific Inc.
Product Code: MRR-437E9896A512

The Genetic Testing Market was valued at USD 15.44 billion in 2025 and is projected to grow to USD 17.60 billion in 2026, with a CAGR of 14.44%, reaching USD 39.72 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.44 billion
Estimated Year [2026] USD 17.60 billion
Forecast Year [2032] USD 39.72 billion
CAGR (%) 14.44%

An expansive introduction to the genetic testing ecosystem emphasizing clinical integration, consumer engagement, regulatory evolution, and operational scalability

The genetic testing landscape is undergoing a period of rapid refinement driven by advances in molecular technologies, expanded clinical applications, and heightened consumer interest in personalized health. Diagnostic laboratories, hospitals, and direct-to-consumer channels are integrating sophisticated assays into workflows, while software and services increasingly enable interpretation, reporting, and longitudinal data management. These converging trends are reshaping how providers, payers, and patients interact with genetic information.

Moreover, regulatory agencies and professional societies are clarifying standards for analytic validity, clinical utility, and data privacy, which in turn influence adoption patterns across clinical and consumer settings. Operational scalability remains a parallel priority as laboratories balance throughput, quality control, and supply chain resilience. As stakeholders navigate these dynamics, strategic choices around technology platforms, test portfolios, and distribution models will determine competitive positioning and the ability to capture clinical value. Consequently, stakeholders should prioritize rigorous validation, clear clinical pathways, and interoperable data infrastructures that support integration with electronic health records and value-based care initiatives.

Transformative shifts in genetics driven by integrated laboratory platforms, cloud-native interpretation, evolving delivery models, and strengthened regulatory frameworks

The landscape of genetic testing is shifting from siloed assays toward integrated, data-driven offerings that combine laboratory capabilities with interpretive software and ongoing clinical decision support. Sequencing and PCR-based platforms are being complemented by gene expression and microarray tools, while cloud-enabled bioinformatics is accelerating turnaround and enhancing variant interpretation. These technological convergences enable more comprehensive diagnostic panels and foster multi-modal testing strategies across clinical pathways.

Concurrently, market actors are rethinking delivery models. Diagnostic laboratories and hospitals are optimizing in-house testing for high-acuity needs, while outsourced partners and software vendors provide specialized services and analytics. Direct-to-consumer access continues to expand awareness of genetic health, prompting clinicians and payers to refine utility frameworks. Regulatory and reimbursement trends are encouraging standardized reporting and evidence generation, which in turn support broader clinical adoption. Ultimately, the most transformative shifts balance technological innovation with validated clinical utility, robust data governance, and sustainable operational models.

Assessment of how the 2025 tariff measures have reshaped procurement, supply chains, and operational resilience for genetic testing stakeholders

The imposition of tariffs by the United States in 2025 has introduced new variables into procurement, supply chain strategy, and cost management across the genetic testing ecosystem. Manufacturers of instruments and consumables have had to reassess sourcing strategies, and laboratories have been prompted to evaluate the total landed cost of imported reagents and equipment. In response, stakeholders are reallocating purchasing volumes, intensifying supplier diversification, and seeking regional manufacturing options to mitigate exposure to tariff-related price fluctuations.

These adjustments are cascading through operational planning. Some laboratories are lengthening inventory reorder cycles and strengthening supplier contracts to buffer against potential customs delays. Others are accelerating validation of alternative platforms that rely on different component mixes or domestic supply chains. At the same time, strategic collaborations between vendors and laboratories are being used to share risk, co-develop localized supply solutions, and provide bundled service agreements that reduce transactional vulnerabilities. Looking ahead, tariff-related pressures are likely to reinforce the value of supply chain transparency, dual-sourcing, and client-vendor partnerships that prioritize continuity of clinical testing services.

Comprehensive segmentation insights to align product development, commercialization, and operational priorities across technologies, test types, applications, channels, and end users

A granular understanding of market segmentation is essential for designing product strategies and prioritizing investments. When viewed through the lens of product categories, stakeholders must differentiate between consumables and equipment, which drive recurring revenue and capital expenditure cycles, and software and services, which create long-term client relationships through analytics, reporting, and workflow integration. Each product category imposes different go-to-market requirements and service architectures.

Considering test type segmentation, payer acceptance and clinical workflows vary significantly across carrier testing, diagnostic testing, newborn screening, pharmacogenomics, preimplantation testing, prenatal testing, and presymptomatic and predictive testing. Consequently, product development should be tailored to the unique evidentiary and regulatory expectations of each test type. From a technology standpoint, choices among cytogenetics, DNA sequencing, gene expression profiling, microarrays, and PCR influence assay sensitivity, throughput, and cost-per-test, and should align with intended clinical or consumer applications.

Application-oriented segmentation reveals differing demand dynamics across autoimmune disorders, cancer, chronic diseases, genetic disorders, and neurodegenerative diseases, each requiring distinct validation datasets and clinical decision frameworks. Distribution channel distinctions between offline and online models determine how tests are marketed, consented, and delivered, while end-user segmentation-diagnostic laboratories, home setting, and hospitals and clinics-shapes service level requirements, integration needs, and training obligations. Together, these segment perspectives provide a roadmap for aligning R&D, commercial, and operational priorities to real-world pathways of adoption.

Regional perspectives on regulatory nuance, adoption velocity, and supply chain localization across the Americas, Europe Middle East Africa, and Asia-Pacific markets

Regional dynamics continue to exert strong influence on adoption curves, regulatory expectations, and partnership strategies. In the Americas, clinical integration and consumer awareness are both driving demand for diverse testing portfolios, and stakeholders benefit from established reimbursement pathways and dense clinical networks that support trialing innovative diagnostics. Transitioning toward integrated care models, institutions are increasingly incorporating genomic insights into chronic disease management and oncology pathways, which in turn encourages investment in local laboratory capabilities and interpretive services.

Across Europe, the Middle East, and Africa, heterogeneity in regulatory frameworks and healthcare infrastructure yields a mosaic of opportunities. Some jurisdictions emphasize centralized newborn screening and national genomic initiatives, while others are scaling private laboratory services. This variability requires adaptive market entry strategies that accommodate differing certification requirements and data protection norms. Meanwhile, in the Asia-Pacific region, rapid technology adoption and expanding clinical laboratory capacity are supporting growth in both hospital-based testing and consumer-facing services. Regional supply chains and manufacturing hubs are also maturing, offering opportunities to localize production and reduce dependence on cross-border logistics. Taken together, these regional characteristics necessitate tailored commercial models, regulatory engagement, and localized partnerships to achieve sustainable adoption.

Key company dynamics revealing strategic differentiation through platform integration, partnerships, data interoperability, and operational excellence

Competitive dynamics in genetic testing are shaped by a mix of incumbent instrument manufacturers, specialized assay developers, bioinformatics providers, and integrated service laboratories. Leading actors are differentiating through platform breadth, interpretive algorithms, and value-added services such as variant curation, real-world evidence generation, and clinician education. As interoperability and data standards become more critical, companies that invest in robust APIs and EHR integration gain a competitive edge in clinical settings.

Strategic approaches also vary: some firms prioritize vertical integration by combining instrumentation, consumables, and proprietary assays to capture margin across the value chain, while others focus on partnerships and open-platform strategies that accelerate adoption through third-party validations. In addition, alliance-building with hospital systems, academic centers, and payers supports evidence development and aids in securing coverage pathways. Finally, operational excellence-demonstrated through consistent quality metrics, scalable logistics, and responsive customer support-remains a decisive factor for laboratories and health systems when selecting vendor partners.

Actionable recommendations for executives to build platform flexibility, supply chain resilience, data interoperability, regulatory engagement, and recurring clinical services

Industry leaders should adopt a multi-pronged approach to secure long-term relevance and influence in genetic testing. First, prioritize investments in modular platforms that allow rapid adoption of new assays and enable flexible service tiers; this reduces time-to-market for emerging clinical applications and supports scalability across diverse client types. Second, institutionalize supplier diversification and regional sourcing to mitigate tariff and logistics disruptions while preserving quality and validation timelines.

Third, elevate data stewardship and interoperability by implementing standardized reporting formats, API-driven integrations with electronic health records, and transparent variant interpretation frameworks that can be audited by external stakeholders. Fourth, engage proactively with regulators, payers, and professional societies to co-develop evidence generation strategies that demonstrate clinical utility and inform coverage policies. Fifth, expand service offerings beyond raw testing to include longitudinal patient monitoring, clinician decision support, and curated databases that create recurring revenue and strengthen client relationships. Together, these actions will position organizations to capitalize on clinical demand while managing operational risk and regulatory complexity.

Robust mixed-methods research methodology combining stakeholder interviews, literature synthesis, triangulation, and expert peer review to ensure practical and validated insights

The research methodology underpinning this analysis combined qualitative and quantitative approaches to produce actionable, reproducible insights. Primary research included structured interviews with laboratory directors, hospital procurement leads, clinical geneticists, and commercial executives to surface first-hand perspectives on technology choice, reimbursement challenges, and operational priorities. Secondary research encompassed peer-reviewed literature, technical white papers, regulatory guidance documents, and publicly available corporate disclosures to contextualize primary findings and ensure alignment with contemporary standards.

Data synthesis employed triangulation techniques to reconcile divergent stakeholder views and to validate thematic findings against documented practice patterns. The methodology emphasized transparency: testing modalities were mapped against clinical pathways, and segmentation schemas were cross-checked with stakeholder interviews to ensure practical relevance. Where applicable, sensitivity checks were used to examine the robustness of conclusions under alternative operational scenarios. Finally, findings were peer-reviewed by subject matter experts with clinical and laboratory leadership experience to ensure accuracy and real-world applicability.

Conclusion synthesizing strategic imperatives for responsible adoption, operational rigor, regulatory engagement, and partnership-driven growth in genetic testing

In summary, the genetic testing sector stands at an inflection point where technological maturity, regulatory refinement, and evolving care models intersect to create significant strategic opportunities. Organizations that align product development with validated clinical utility, invest in interoperable data infrastructure, and strengthen supply chain resilience will be best positioned to capture long-term value. At the same time, proactive regulatory engagement and rigorous evidence generation remain essential to expand clinical adoption and ensure sustainable reimbursement pathways.

Looking ahead, success will favor entities that balance innovation with operational rigor, cultivate partnerships across clinical and commercial stakeholders, and design services that integrate seamlessly into existing care workflows. By focusing on these priorities, market participants can accelerate responsible adoption of genetic testing technologies, improve patient outcomes, and build resilient business models that withstand regulatory and macroeconomic headwinds.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Genetic Testing Market, by Product

  • 8.1. Consumables & Equipment
  • 8.2. Software & Services

9. Genetic Testing Market, by Test Type

  • 9.1. Carrier Testing
  • 9.2. Diagnostic Testing
  • 9.3. New Born Screening
  • 9.4. Pharmacogenomics
  • 9.5. Preimplantation Testing
  • 9.6. Prenatal Testing
  • 9.7. Presymptomatic & Predictive Testing

10. Genetic Testing Market, by Technology

  • 10.1. Cytogenetics
  • 10.2. DNA Sequencing
  • 10.3. Gene Expression Profiling
  • 10.4. Microarrays
  • 10.5. PCR

11. Genetic Testing Market, by Application

  • 11.1. Autoimmune Disorders
  • 11.2. Cancer
  • 11.3. Chronic Diseases
  • 11.4. Genetic Disorders
  • 11.5. Neurodegenerative Diseases

12. Genetic Testing Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Genetic Testing Market, by End-User

  • 13.1. Diagnostic Laboratories
  • 13.2. Home Setting
  • 13.3. Hospitals & Clinics

14. Genetic Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Genetic Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Genetic Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Genetic Testing Market

18. China Genetic Testing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Agilent Technologies, Inc.
  • 19.7. Becton, Dickinson and Company
  • 19.8. Bio-Rad Laboratories, Inc.
  • 19.9. Bio-Techne Corporation
  • 19.10. Bruker Corporation
  • 19.11. Centogene N.V.
  • 19.12. Color Health, Inc.
  • 19.13. CooperSurgical Inc.
  • 19.14. Editas Medicine, Inc.
  • 19.15. Eugene Labs Pty Ltd.
  • 19.16. Eurofins Scientific SE
  • 19.17. F. Hoffmann-La Roche AG
  • 19.18. Fulgent Genetics, Inc.
  • 19.19. Gene by Gene, Ltd.
  • 19.20. GeneDx, LLC
  • 19.21. Illumina, Inc.
  • 19.22. Invitae Corporation
  • 19.23. Laboratory Corporation of America Holdings
  • 19.24. Living DNA Ltd.
  • 19.25. Macrogen, Inc.
  • 19.26. MyHeritage Ltd.
  • 19.27. Myriad Genetics, Inc.
  • 19.28. Natera, Inc.
  • 19.29. Newtopia Inc.
  • 19.30. PathogenDx Corporation
  • 19.31. PerkinElmer Inc.
  • 19.32. Qiagen N.V.
  • 19.33. Quest Diagnostics Incorporated
  • 19.34. Sanofi S.A.
  • 19.35. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENETIC TESTING MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENETIC TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENETIC TESTING MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GENETIC TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENETIC TESTING MARKET SIZE, BY CONSUMABLES & EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENETIC TESTING MARKET SIZE, BY CONSUMABLES & EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENETIC TESTING MARKET SIZE, BY CONSUMABLES & EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENETIC TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENETIC TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENETIC TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENETIC TESTING MARKET SIZE, BY CARRIER TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENETIC TESTING MARKET SIZE, BY CARRIER TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENETIC TESTING MARKET SIZE, BY CARRIER TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENETIC TESTING MARKET SIZE, BY NEW BORN SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENETIC TESTING MARKET SIZE, BY NEW BORN SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENETIC TESTING MARKET SIZE, BY NEW BORN SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENETIC TESTING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENETIC TESTING MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENETIC TESTING MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENETIC TESTING MARKET SIZE, BY PRESYMPTOMATIC & PREDICTIVE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENETIC TESTING MARKET SIZE, BY PRESYMPTOMATIC & PREDICTIVE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENETIC TESTING MARKET SIZE, BY PRESYMPTOMATIC & PREDICTIVE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENETIC TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENETIC TESTING MARKET SIZE, BY CYTOGENETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENETIC TESTING MARKET SIZE, BY CYTOGENETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENETIC TESTING MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENETIC TESTING MARKET SIZE, BY DNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENETIC TESTING MARKET SIZE, BY DNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENETIC TESTING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENETIC TESTING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENETIC TESTING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENETIC TESTING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENETIC TESTING MARKET SIZE, BY MICROARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENETIC TESTING MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENETIC TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENETIC TESTING MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENETIC TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENETIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENETIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENETIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENETIC TESTING MARKET SIZE, BY CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENETIC TESTING MARKET SIZE, BY CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENETIC TESTING MARKET SIZE, BY CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENETIC TESTING MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENETIC TESTING MARKET SIZE, BY CHRONIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENETIC TESTING MARKET SIZE, BY CHRONIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENETIC TESTING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENETIC TESTING MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENETIC TESTING MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENETIC TESTING MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENETIC TESTING MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENETIC TESTING MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENETIC TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENETIC TESTING MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENETIC TESTING MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENETIC TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENETIC TESTING MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENETIC TESTING MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENETIC TESTING MARKET SIZE, BY HOME SETTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENETIC TESTING MARKET SIZE, BY HOME SETTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENETIC TESTING MARKET SIZE, BY HOME SETTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS GENETIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENETIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 145. GCC GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GCC GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 147. GCC GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. GCC GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. GCC GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. GCC GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 166. G7 GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. G7 GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 168. G7 GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. G7 GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. G7 GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. G7 GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. G7 GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 173. NATO GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. NATO GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 175. NATO GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. NATO GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. NATO GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. NATO GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. NATO GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)